Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Secukinumab Sails Through Advisory Panel, Bodes Well For IL-17 Class

This article was originally published in The Pink Sheet Daily

Executive Summary

Unanimous advisory committee vote positions Novartis’ secukinumab to beat Lilly and Amgen/AstraZeneca competitors to market; panel supportive of Novartis’ preferred dose, letting other dosing issues be further explored post-market.

You may also be interested in...



Sun’s Tildrakizumab Deal: A Calculated Bet?

If approved, tildrakizumab, licensed in globally by Sun Pharma but developed by Merck, will be pitted against established competitors in a crowded market of advanced biologics for plaque psoriasis. But experts believe several advantages can help the top Indian generic firm leap into the wide world of dermatology and anti-inflammatory compounds.

Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into

The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.

Medicare Payment Cuts For Vaccines: MedPac Suggests Moving To New WAC-Reimbursement Formula

Proposal, which could be formally endorsed by MedPac this spring, would lower the payment rates for vaccines while simultaneously moving all preventative vaccine coverage to Medicare Part B. Commission signals further cuts to payment rate, through an average sales priced-based methodology that might eventually be recommended.

Topics

Related Companies

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel